Biomarin Pharmaceutical Inc. (BMRN)
BioMarin's First-Quarter Earnings & Sales Beat Estimates
BMRN reports encouraging first-quarter results. The company reiterates its financial guidance for 2025.
BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $0.71 per share a year ago.
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility
The old idiom "blink, and you'll miss it" might be the best descriptor of the historic volatility we've witnessed on Wall Street over the trailing week, as of this writing on April 9.
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?
BioMarin (BMRN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.
What Makes BioMarin (BMRN) a New Buy Stock
BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BMRN vs. CSLLY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion
BioMarin Pharmaceutical Inc.'s primary endpoint was met in the phase 3 Pegasus study, which used Palynziq for the treatment of adolescent patients ages 12 - 17 with phenylketonuria. The company is set to file regulatory applications to expand the label of Palynziq for phenylketonuria patients in both the U.S. and European territories in 2nd half of 2025. The global phenylketonuria market size is estimated to reach $2.02 billion by 2032.
